Felipe Nathanael Coelho Vaz

Felipe Nathanael Coelho Vaz

Auto-generated profile, based on publicly available information

Felipe Nathanael Coelho Vaz

Universidade Estadual do Centro Oeste

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2017 in F1000Research
Verified
Journal Article
Open access
PDF file
FVFelipe Nathanael Coelho Vaz
Felipe Nathanael Coelho Vaz
LTLuana Bortoluzzi Trombim
Luana Bortoluzzi Trombim
GFGuilherme Barroso L. de Freitas
Guilherme Barroso L. de Freitas
MHMaria Vaitsa Loch Haskel
Maria Vaitsa Loch Haskel
GSGiovana dos Santos
Giovana dos Santos
Juliana Sartori BoniniJuliana Sartori Bonini
Juliana Sartori Bonini
Background: Elderly patients frequently have concomitant diseases, triggering the necessity of utilizing several different medications, which can cause adverse events associated with therapy, called polypharmacy. This study aimed to evaluate the main concomitant diseases with Alzheimer's disease (AD) and discuss possible interactions between drugs utilized to treat dementia and its comorbidities, and indicate safe medicines for patients with AD. Methods: 41 individuals with AD who withdraw medicines for dementia from the Brazilian public health system (SUS) participated in this study. Data collection was performed using three questionnaires: 1) Clinical Dementia Rating, to verify disease stage; 2) Mini–mental state examination, to measure cognitive impairment; and 3) Sociodemographic analysis, to evaluate concomitant diseases, utilized drugs, drug-drug interactions, among other demographic variables. Statistical analyses were performed using SPSS and data was presented as relative frequency. Results: The results of this study showed that the most frequent concomitant diseases with AD are: systemic arterial hypertension, depression, diabetes mellitus, and hypercholesterolemia. Polypharmacy was observed in 95.12% of patients. The pharmacologic classes that presented interactions with AD medications were anxiolytics, antidepressants, antipsychotics, antihypertensives, and antidiabetics. Conclusion: In the present study, polypharmacy in patients with AD and other concomitant diseases has been characterized. The average number of drugs that these patients ingested was seven per day, and this leads to drug interactions, which are potentially damaging to the body. Consequently, we have tried to reduce these interactions, by suggesting drugs that are safer, for example furosemide instead of amlodipine to treat hypertension.

1 April 2018 in Cadernos de Prospecção
Verified
Journal Article
Open access
PDF file
NPNilane Françoise Patel
Nilane Françoise Patel
BSBruno Moreira Soares
Bruno Moreira Soares
DRDaniele Fernanda Renzi
Daniele Fernanda Renzi
APAndressa Razera Pezoti
Andressa Razera Pezoti
JWJéssica Wouk
Jéssica Wouk
FVFelipe Nathanael Coelho Vaz
Felipe Nathanael Coelho Vaz
O Diabetes mellitus (DM) destaca-se como um problema de saúde pública mundial. Diante disso, várias espécies de plantas vêm sendo utilizadas para tratar e/ou combater os sintomas do DM. O objetivo deste estudo foi avaliar os efeitos da ingestão subcrônica do extrato de Baccharis dracunculifolia, em modelo animal de DM. Foram utilizados 56 ratos machos da linhagem Wistar, tratados por 28 dias. O modelo de DM tipo I foi induzido pela administração de 60 mg/kg de estreptozotocina. O grupo CB demonstrou 14,8% (p<0.05) menor consumo de ração que o grupo DB200. Quanto à ingestão hídrica, o grupo CDT teve maior ingesta (44,1%; p<0.05) com relação aos grupos tratados. Na glicemia capilar em jejum e pós-prandial, os grupos tratados apresentaram redução de 54,3% a 63,4% ao jejum e 37,9% a 45% no pós-prandial. Conclui-se que o extrato metanólico de B. dracunculifolia reduziu os níveis glicêmicos em ratos diabéticos tipo I.